Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells

B. Jiang and M. Xue

Department of Gynecology and Obstetrics, the Third Xiangya Hospital, Central South University, Changsha, China

Corresponding author: M. Xue
E-mail: MinXueghj@163.com

Received January 25, 2015
Accepted May 8, 2015
Published September 8, 2015
DOI http://dx.doi.org/10.4238/2015.September.8.8

ABSTRACT. The human papillomavirus (HPV)16 E6 and E7 correlation with chemokine ligand (CCL)20 expression and Langerhans cells (LCs) in cervical lesions was investigated. We enrolled 43 patients with surgically treated cervical lesions from the Department of Gynecology in our hospital, and 20 controls without cervical lesions. Subjects were divided by pathology: HPV16(-) and HPV16(+) normal cervical groups (N = 10 each), and HPV16(+) cervical intraepithelial neoplasia (CIN), cervical invasive carcinoma (N = 15 each), and in situ carcinoma (N = 13) groups. E6, E7, the LC surface marker CD1a, and CCL20 were analyzed by immunohistochemistry. E6 and E7 in HPV16-type lesions were correlated with CCL20 and LCs. The average high power field cell numbers of CD1a+ LCs in the HPV(-) and HPV(+) normal cervix groups, and the CINI-II, CINIII in situ and cervical carcinoma groups were 22.89 ± 4.84, 13.7 ± 2.26, 9.2 ± 1.68, 5.9 ± 1.59, and 5.5 ± 1.58, respectively. Significant between-group differences existed except between cervical carcinoma and CINIII groups (P < 0.05). CCL20+ rates in each group were 70, 60, 60, 15.38, and 13.33%, respectively.
E6/E7-positive expression rates in each group were 20/20, 66.7/66.7, 76.9/69.2, and 86.67/73.3%, respectively. CCL20 was positively correlated with CD1a \((r = 0.649)\), and negatively correlated with E7 \((r = -0.946)\) and E6 \((r = -0.949)\). CD1a was negatively correlated with E6 \((r = -0.632)\) and E7 \((r = -0.632)\). Downregulation of CCL20 leading to LC decline is a key factor in cervical lesions. High-risk HPV-type lesions might inhibit the chemokine CCL20 through E6 and E7 to escape the immune response.

**Key words:** Cervix; CCL20; Langerhans cells; E6; E7

**INTRODUCTION**

Cervical cancer is a common malignant tumor and has the highest incidence among gynecological tumors. The rate of cervical cancer in women is rising each year, and it has become a large threat to women’s health and a substantial burden on the global economy (Hussain et al., 2014; Skaabøy et al., 2014). Its morbidity and mortality have remained at high levels in China (Du et al., 2014; Xu et al., 2014). Although the occurrence and development of cervical cancer is a long-term and gradual process caused by multiple carcinogenic factors, persistent high-risk human papillomavirus (HPV)-type infection represents one of the clearest etiologies. Persistent expression of the E6 and E7 proteins of the high-risk type HPV16 virus is a key risk factor for cervical cell transformation and the maintenance of a malignant phenotype (Gan et al., 2014; He et al., 2014), and represents the primary mechanism by which the virus escapes host cell immune surveillance after HPV infection. Thus, the immune escape mechanism of HPV has become the focus of current research (Niebler et al., 2013; Nahvijou et al., 2014).

Langerhans cells (LCs) are primarily expressed in the epidermis and are a kind of immature dendritic cell. LCs are the main immune cell to act as antigen-presenting cells for presentation of the HPV virus to trigger an immune response (Rios-Yuil et al., 2014).

LC migration depends on the chemokines in the environment and the specific chemokine receptors on the LCs. Chemokine ligand (CCL)20 is a chemokine that is formed and secreted by keratinocytes, and LCs can express the CCL20 receptor chemokine receptor (CCR)6 (Amador-Molina et al., 2013; Da Silva et al., 2014). LCs only express CXCR4 and CCR6 in normal skin; normal skin keratin formation cells and venous endothelial cells express CCL20; while myeloid dendritic cell precursor cells lose their ability to react to the CCR2 ligand but gain the ability to react to the CCR6 ligand, CCL20, when they differentiate into LCs. It was thought that CCL20 might play an important role in regulating LCs and the selective entry of their precursor cells into the epidermis (Nakayama et al., 2011; Sperling et al., 2012). There is still a lack of information regarding whether CCL20 can influence HPV infection. It has been suggested that HPV infection can downregulate CCL20 (Wang et al., 2010); however, whether the HPV16 E6 and E7 proteins are correlated with LCs and CCL20 is still controversial. In this study, we tried to investigate the correlation of E6 and E7 in high-risk HPV16-type infection with CCL20 and LCs within cervical lesions.
MATERIAL AND METHODS

Subjects

We enrolled 43 patients with cervical lesions who had been treated by surgery in the Department of Gynecology in the Third Xiangya Hospital of Central South University; the average patient age was 46.38 ± 6.61 years. There were 15 patients in the cervical intraepithelial neoplasia (CIN)I-CINI group, 13 in the CINIII-carcinoma in situ group, and 15 patients in the cervical invasive carcinoma group. All of the patients were infected by HPV16 alone and the surgery represented their initial treatment. All specimens were diagnosed by pathology and patients had received no preoperative chemotherapy or radiation therapy intervention. Exclusion criteria included metastatic tumor, cervical tumor combined with other tumors, a history of preoperative radiotherapy or chemotherapy, combined autoimmune disease, and a history in receipt of oral immune inhibitors. An additional 20 subjects with normal cervixes were collected with the average age of 37.8 ± 3.56 years. Among these, 10 were in the HPV(-) normal cervix group and 10 were in the HPV16(+) normal cervix group. The general clinical information showed no statistical difference between the two groups (P > 0.05). Subjects were informed and had signed informed consent, and the research content was approved by the hospital Ethics Committee.

Main instruments and reagents

The CD1a monoclonal antibody for immunohistochemistry was bought from Maxim Biotechnology Co., Ltd. (Fuzhou, China). The CCL20 monoclonal antibody, E6 protein monoclonal antibody, and E7 protein monoclonal antibody were obtained from Bioss Biological Company (Beijing, China). The streptavidin-peroxidase (SP) kit was bought from the Zhongshan Golden Bridge Bio-Technology Co., Ltd. (Beijing, China).

Methods

Grouping

According to their cervical lesion progression and HPV16 infection status, the subjects were divided into four groups: HPV(-) normal cervical group (N = 10), HPV16(+) cervical normal group (N = 10), HPV16(+) CIN group (N = 28), and HPV16(+) cervical invasive carcinoma group (N = 15). No significant difference of the general information was detected among each group (P > 0.05).

Immunohistochemistry

The immunohistochemical SP method was utilized to detect the expression of LCs, and E6, E7, and CCL20 proteins. Tissue samples were collected from the surgical resection, fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned (5 μm). Paraffin sections were dewaxed and the endogenous peroxidase was blocked with 3% H₂O₂ solution. After being washed by 0.01 M sodium citrate buffer, pH 6.0, the antigen was repaired. Monoclonal antibodies for E6, E7, CD1a, or CCL20 (Santa Cruz, USA) were applied at 1:500 dilutions for
incubation overnight at 4°C. The slices were incubated with goat anti-mouse IgG conjugated with horseradish peroxidase (Invitrogen, USA) and colorized by DAB.

The results were evaluated as follows: CD1a-positive yellow or brown cells with irregular dendritic protrusions, identified as Langerhans cells, were counted at high magnification under a microscope. The immunoreactive score was applied to evaluate protein and CCL20 expression. Five fields of vision were selected on each slide for evaluation based on brown positive intensity and area. For each field of vision, positive intensity with no coloring, light yellow, weak brown, and brown were scored 0, 1, 2, and 3 points, respectively; positive staining area with no color, color area less than 25, 25-50%, 50-75%, and >75% were scored 0, 1, 2, and 3 points, respectively. The two scores were added and the five view score results were averaged. A score of 0-1 represented a negative (-) result, 2 represented weakly positive (+), 3-4 represented moderately positive (+ +), and 5-6 represented strong positive (+ + +); scores of 2-6 represented positive results.

Statistical analysis

Enumeration data was analyzed by the chi-square test and measurement data are reported as means ± standard deviation. ANOVA and t-test were chosen for analysis when appropriate. Logistic regression was applied for correlation analysis between E6 and E7, CCL20, and CD1a protein results. P values of less than 0.05 were considered to be significant.

RESULTS

CD1a expression

CD1a+ LCs were primarily distributed in the membranes or cytoplasm of the middle and basic layers in the squamous epithelium, with irregular dendritic protrusions on morphology. The average high power fields of CD1a+ LCs in the HPV(-) normal cervix group, the HPV(+) normal cervix group, and the CINI-II, CINIII in situ carcinoma, and cervical carcinoma groups were 22.89 ± 4.84, 13.7 ± 2.26, 9.2 ± 1.68, 5.9 ± 1.59, and 5.5 ±1.58, respectively (Figure 1). The difference between each group was statistically significant except between the cervical carcinoma and CINIII groups (P < 0.05).

CCL20 expression

CCL20 was primarily expressed in the cytoplasm or membrane of the squamous epithelium in normal cervix. It was expressed less in the CINIII-carcinoma in situ and cervical invasive carcinoma tissues (Figure 2). The positive rate of CCL20 in each group was 70, 60, 60, 15.38, and 13.33%, respectively. Significant differences were observed between the normal cervix and cervical cancer groups, the normal cervix and CINIII-carcinoma in situ groups, the CINI-CINII and cervical cancer groups, and the CINI-CINII and CINIII-carcinoma in situ groups (P < 0.05).

E6 protein expression

E6 protein was predominantly expressed in the nucleus and only weak signals in cy-
toplasm. It exhibited little or no expression in normal cervix, but showed strong expression in CIN and in cervical cancer (Figure 3). The positive expression rate of the E6 protein in each group was 20, 66.7, 76.9, and 86.67%, respectively. Significant differences were found between the expression in the normal cervix group and the CINI-CINII group, the CINIII-carcinoma in situ group, and the cervical cancer group (P < 0.05).

Figure 1. CD1a expression in patients with cervical lesions and controls. A, CD1a expression in the normal cervix group; B, CD1a expression in the cervical intraepithelial neoplasia (CIN)I group; C, CD1a expression in the CINIII group; D, CD1a expression in the cervical carcinoma group. Immune reactivity was visualized by DAB substrate (brown) and was counter-stained with hematoxylin (blue). Magnification, 200X.

Figure 2. CCL2 expression in patients with cervical lesions and controls. A, CCL2 expression in the normal cervix group; B, CCL2 expression in the cervical intraepithelial neoplasia (CIN)I group; C, CCL2 expression in the CINIII group; D, CCL2 expression in the cervical carcinoma group. Immune reactivity was visualized by DAB substrate (brown) and was counter-stained with hematoxylin (blue). Magnification, 200X.
Figure 3. E6 protein expression in patients with cervical lesions and controls. A. E6 protein expression in the normal cervix group; B. E6 protein expression in the cervical intraepithelial neoplasia (CIN) I group; C. E6 protein expression in the CIN III group; D. E6 protein expression in the cervical carcinoma group. Immune reactivity was visualized by DAB substrate (brown) and was counter-stained with hematoxylin (blue). Magnification, 200X.

E7 protein expression

E7 protein expressed mainly in the nucleus but only weakly in cytoplasm. It exhibited little or no expression in normal cervical tissue, but exhibited strong expression in CIN and in cervical cancer (Figure 4). The positive expression rate of E6 protein in each group was 20, 66.7, 69.2, and 73.3%, respectively. The normal cervix group showed significant differences with the other groups for E7 expression levels (P < 0.05).

Figure 4. E7 protein expression in patients with cervical lesions and controls. A. E7 protein expression in the normal cervix group; B. E7 protein expression in the cervical intraepithelial neoplasia (CIN) I group; C. E7 protein expression in the CIN III group; D. E7 protein expression in the cervical carcinoma group. Immune reactivity was visualized by DAB substrate (brown) and was counter-stained with hematoxylin (blue). Magnification, 200X.
Correlation of CD1a and CCL20 with E6 and E7

The correlations of CD1a and CCL20 with E6- and E7-positive results were further analyzed. CCL20 was positively correlated with CD1a \( (r = 0.649) \), and significantly negatively correlated with E7 and E6 \( (r = -0.946, r = -0.949, P < 0.05) \), respectively. The CD1a-positive rate was also obviously negatively correlated with E6 and E7 \( (r = -0.632, r = -0.632, P < 0.05) \), respectively.

DISCUSSION

Multiple factors including bacteria, viruses, microbes, precocious sexuality, promiscuity, multiple birth, and genetic susceptibility can cause cervical lesions and even cervical cancer (Zamaniah et al., 2014; Zeng et al., 2014). Numerous epidemiologic and molecular biology studies have confirmed that the HPV is closely related to the occurrence and development of genital tract epithelial malignant tumors and precancerous lesions. In particular, the persistent infection with high-risk HPV has been identified as the main etiological factor for cervical cancer. HPV-DNA can be detected in nearly 99.7% of cervical cancers. At present, the pool of individuals with HPV infection is becoming younger, and studies have shown that HPV16 exhibits the strongest pathogenic infection (Nessa et al., 2014). The persistent expression of the HPV proteins E6 and E7 is a high risk factor for cervical cancer. To date, many mechanisms of HPV carcinogenesis have been investigated; for example, the oncogenes E6 and E7 can promote tumorigenesis through a P53-independent pathway, and HPV can cause cells to undergo transformation through the activation of telomerase. On the other hand, it has also been found that HPV infection can escape immune surveillance and response. Thus, research on the mechanisms underlying the latter phenomenon has important significance (Durzynska, 2014).

LCs, as important antigen-presenting cells for the capture and management of the HPV virus, exist in the epidermis. They can migrate from the epidermis to regional lymph nodes through the basement membrane of the skin and via the lymph channels, and can develop into finger dendritic cells. The number and density of LCs have been shown to be significantly reduced in the presence of HPV infection. HPV can limit the immune response by reducing LC number and density, which allows the persistent HPV infection of cervical epithelial cells. Decreased chemokine release mediated by HPV16 infection might also be an important mechanism underlying LC number reduction. The expression of cytokines such as TGF-β1 is reduced in precancerous lesions of the uterine cervix. TGF-β1 can promote LC progenitor cells to enter the skin and induce their differentiation. Downregulation of TGF-β1 can affect LC infiltration and maturation in the infected area directly. HPV infection can also reduce the expression of IL-1α, IL-1β, and granulocyte-macrophage colony stimulating factor (GM-CSF), factors crucial for LC migration and maturation (Ancuța et al., 2014). GM-CSF is a cytokine that can mediate the gathering of LCs at the epidermis and is decreased significantly in cervical epithelium infected by HPV. Thus, LC number reduction after HPV infection is closely related to the decrease of chemokines. CCL20 is only expressed in inflammatory epithelial and mucosal tissue. CCR6, as the single receptor with high affinity for CCL20, is primarily expressed on the surface of LCs, and on activated T- and B-cells. In combination with its specific receptor CCR6, CCL20 plays a crucial role in the process of LC gathering and chemotaxis in cervical epithelial tissue (Giannini et al., 2002; Guess and McCance, 2005;
Our results confirmed that LC numbers were reduced in accordance with the severity of the cervical lesions; CCL20 was decreased by HPV infection; and E6 and E7 protein was also upregulated in proportion with the severity of the disease. The results demonstrated that CCL20 is therefore positively correlated with CD1a; E6 and E7 are negatively correlated with CCL20; and CD1a showed a negative correlation with E6 and E7.

In summary, our research confirmed that downregulation of CCL20 leading to LC decline is a key factor in cervical lesions. High-risk HPV-type infection might inhibit the chemokine CCL20 through E6 and E7 to escape the immune response. This finding might provide the basis for further investigation into the mechanism of HPV immune response evasion in cervical lesions.

Conflict of interest

The authors declare no conflict of interest.

ACKNOWLEDGMENTS

We thank the anonymous reviewers for reviewing this manuscript.

REFERENCES


LCs and CCL20 in HPV-positive cervical lesions


